Crinetics Pharmaceuticals, Inc. (CRNX)
NASDAQ: CRNX · Real-Time Price · USD
38.15
-0.47 (-1.22%)
At close: Apr 28, 2026, 4:00 PM EDT
37.90
-0.25 (-0.66%)
After-hours: Apr 28, 2026, 7:22 PM EDT
Crinetics Pharmaceuticals Stock Forecast
Stock Price Forecast
The 8 analysts with 12-month price forecasts for Crinetics Pharmaceuticals stock have an average target of 76.75, with a low estimate of 52 and a high estimate of 97. The average target predicts an increase of 101.18% from the current stock price of 38.15.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Crinetics Pharmaceuticals stock from 8 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Nov '25 | Dec '25 | Jan '26 | Feb '26 | Mar '26 | Apr '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 4 | 4 | 4 | 3 | 2 |
| Buy | 6 | 6 | 6 | 6 | 6 | 6 |
| Hold | 2 | 2 | 1 | 1 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 12 | 12 | 11 | 11 | 9 | 8 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Citizens | Citizens | Buy Maintains $96 → $97 | Buy | Maintains | $96 → $97 | +154.26% | Apr 28, 2026 |
| Citizens | Citizens | Buy Maintains $105 → $96 | Buy | Maintains | $105 → $96 | +151.64% | Mar 2, 2026 |
| Goldman Sachs | Goldman Sachs | Hold → Strong Buy Upgrades $67 | Hold → Strong Buy | Upgrades | $67 | +75.62% | Jan 12, 2026 |
| Citizens | Citizens | Buy Maintains $108 → $105 | Buy | Maintains | $108 → $105 | +175.23% | Jan 8, 2026 |
| Morgan Stanley | Morgan Stanley | Buy Maintains $77 → $80 | Buy | Maintains | $77 → $80 | +109.70% | Jan 6, 2026 |
Financial Forecast
Revenue This Year
63.12M
from 7.70M
Increased by 720.10%
Revenue Next Year
179.67M
from 63.12M
Increased by 184.67%
EPS This Year
-5.02
from -4.95
EPS Next Year
-4.27
from -5.02
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | 82.3M | 224.6M | ||||||
| Avg | 63.1M | 179.7M | ||||||
| Low | 36.3M | 130.9M |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | 969.6% | 255.9% | ||||||
| Avg | 720.1% | 184.7% | ||||||
| Low | 371.2% | 107.4% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | -2.99 | -3.05 | ||||||
| Avg | -5.02 | -4.27 | ||||||
| Low | -5.81 | -5.41 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | - | - | ||||||
| Avg | - | - | ||||||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.